Swiss generic drugmaker Sandoz said on Wednesday it would continue discussions with policymakers after U.S. President Donald Trump threatened the industry with steep tariffs unless drugmakers manufacture medicines domestically.
The U.S. Food and Drug Administration has agreed to review Swiss generics drugmaker Sandoz's two generic tirzepatide GLP-1s that, if approved, would rival obesity drugs made by Eli Lilly.
Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.
| Specialty Retail Industry | Consumer Discretionary Sector | Richard Saynor CEO | XFRA Exchange | 799926100 CUSIP |
| CH Country | 23,000 Employees | 14 Apr 2026 Last Dividend | - Last Split | - IPO Date |
Sandoz Group AG is a global leader in the development, manufacture, and marketing of generic pharmaceuticals and biosimilars. Established in 1886, the company has its headquarters in Basel, Switzerland. Sandoz operates globally, offering a wide range of therapeutic solutions aimed at improving patient outcomes. Its mission revolves around making high-quality medicines accessible to people worldwide, leveraging its extensive experience and innovation in the pharmaceutical sector.